Dr. Swagat - Nuclear Theranostic Specialist

15/08/2026

Celebrating the spirit of freedom, unity, and progress that continues to shape India’s journey forward. 🇮🇳

May we keep inspiring new possibilities, embracing innovation, and building a healthier, stronger future together.

Happy Independence Day! 🇮🇳

01/08/2026

Scaling Theranostics Means Solving This One Thing

We celebrate theranostics as one of the most promising frontiers of precision oncology. We project an $11B market, publish glowing trial data, and celebrate accelerated approvals on global stages.

But by over-indexing on clinical success, we are ignoring the brutal logistical math running in the background.

Theranostics is gaining momentum because the science works. But it has a massive operational blind spot: many radiopharmaceuticals decay rapidly. For isotopes with short half-lives, every minute between synthesis and infusion compounds risk. A single missed flight or customs bottleneck doesn't just disrupt a schedule, it can render the dose unusable.

That limitation matters.
The reality of scaling theranostics isn't just a discovery challenge; it's a race against physics. Minimal margin for error, perishable logistics, and high patient vulnerability mean a single logistics delay can leave a patient in a clinic without treatment.

The clinical question is no longer whether radioligand therapy works.

The real question is whether current production and distribution infrastructure can actually deliver it at scale.

To bridge this gap, we need decentralised regional production hubs, predictive real-time supply chain intelligence, and harmonised customs fast-tracks for isotopes.

The theranostics ecosystem cannot scale efficiently with short-lived isotopes without supply chain innovation. We must build the infrastructure to match the science.

29/07/2026

FAPI Alone Isn't Therapy. It's Half a Plan.

FAPI-targeted radionuclide therapy has rapidly emerged as one of the most promising advances in theranostics. By targeting cancer-associated fibroblasts, it expands our ability to treat cancer beyond tumour cells alone.

But one important question is beginning to emerge.

How do we maximise its long-term clinical benefit?
Over the past four years, I have treated more than 100 patients with FAPI-based radionuclide therapy across multiple tumour types.

One observation has become increasingly clear.
The most durable responses are often seen when FAPI is integrated into a comprehensive treatment strategy.

That difference matters.
Cancer is biologically complex. While FAPI targets the tumour microenvironment, combining it with Lutetium-177, Actinium-225, tandem or sandwich radionuclide protocols, chemotherapy, or immunotherapy allows us to address multiple mechanisms of disease simultaneously.

The clinical question is no longer whether FAPI therapy has a role.
The real question is how we should combine FAPI with established therapies to unlock its full potential.

As precision oncology evolves, the future may not belong to one radionuclide alone.
It may belong to selecting the right combinations for the right patient at the right time.
Prospective clinical trials will define the optimal sequencing.

But oncology has repeatedly shown us one lesson:
The greatest breakthroughs rarely come from replacing therapies. They come from combining them intelligently.

29/07/2026

To the ones who saw our light before we ever did. Happy Guru Purnima. 🌸🌸🌸

27/07/2026

19/07/2026

Why Bigger Radiation Isn't Always Better

We often assume that treating cancer requires maximum force, using the hardest hit possible to destroy a tumor. But when it comes to systemic radionuclide therapy, that brute-force mindset is fundamentally outdated.

Traditional beta-emitters rely heavily on the cross-fire effect. Their long-range electrons are excellent at penetrating large, hypoxic tumor masses, but they also sweep through healthy surrounding tissue. For clinicians, this means managing significant collateral damage, particularly haematological toxicity that limits treatment duration.

True clinical precision demands a paradigm shift toward short-range electrons.

By utilising alpha particles or Auger electrons, we leverage highly localised, high-energy radiation that travels only a few cell diameters. This tight microscopic range ensures that we maximise lethal, double-strand cellular DNA damage strictly within the target tumor cells while sparing neighbouring healthy organs. We are talking about absolute spatial precision at the cellular level.

This extreme precision alters the therapeutic index. It eliminates dose-limiting toxicities, preserves bone marrow function, and allows clinicians to confidently clear widespread micrometastatic disease that was previously unreachable without severe systemic failure.

The clinical question is no longer how much radiation we can dump into a patient's body to force a response. The real question is how accurately we can conform that radiation to the micro-environment of the disease.

Modern radionuclide therapy isn't about delivering more radiation. It's about delivering it exactly where biology demands.

17/07/2026

SUVmax: The Number We Overtrust

We quote SUVmax in almost every PET-CT report. It’s the first number oncologists look for, and the metric patients fixate on to gauge if their disease is responding.

But by over-indexing on a single pixel, we are oversimplifying complex tumor biology.
SUVmax is popular because it’s fast and provides an immediate numeric baseline. But it has massive blind spots. Because it only measures the highest metabolic activity in a single pixel, it ignores the rest of the tumor. A massive, heterogeneous mass with a tiny hypermetabolic focus can have the exact same SUVmax as a small, uniform lesion.

That limitation matters.
Factors like patient blood glucose, incubation times, and reconstruction algorithms easily skew this value. More importantly, it completely fails to capture total metabolic tumor volume (MTV) or total lesion glycolysis (TLG) metrics that actually correlate much better with true patient survival.

The clinical question is no longer whether SUVmax has utility.

The real question is whether relying on an isolated pixel causes us to miss the broader metabolic picture.

A complex, heterogeneous disease cannot be understood by looking at its single brightest point. We need to look at the entire landscape.

16/07/2026

Wishing you a blessed Rath Yatra. Jai Jagannath.